Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECORD 4: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE
2006-002402-60Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Bayer. Primary endpoint: Composite venous thromboembolism endpoint. Started Mar 2007; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2006-002402-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002402-60.